RT Journal Article
SR Electronic
T1 Prognostic value of NT-proBNP in patients with severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.07.20031575
DO 10.1101/2020.03.07.20031575
A1 Gao, Lei
A1 Jiang, Dan
A1 Wen, Xue-song
A1 Cheng, Xiao-cheng
A1 Sun, Min
A1 He, Bin
A1 You, Lin-na
A1 Lei, Peng
A1 Tan, Wei-xiao
A1 Qin, Shu
A1 Cai, Guo-qiang
A1 Zhang, Dong-ying
YR 2020
UL http://medrxiv.org/content/early/2020/03/10/2020.03.07.20031575.abstract
AB The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. The cardiac injury was dominate in the process. However, whether N terminal pro B type natriuretic peptide (NT-proBNP) predicted outcome of COVID-19 patients was unknown. The study initially enrolled 102 patients with severe COVID-19 pneumonia from a continuous sample. After screening out the ineligible cases, 54 patients were analyzed in this study. Results found that patients with higher NT-proBNP (above 88.64 pg/mL) level had more risks of in-hospital death. After adjusting for potential cofounders in separate modes, NT-proBNP presented as an independent risk factor of in-hospital death in patients with severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04292964Funding StatementThis study was supported by National Natural Science Foundation of China, 81970203; National Natural Science Foundation of China, 81570212; National Natural Science Foundation of China, 31800976; Chongqing Science and Health Joint Medical Research Project, 2018QNXM024.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.